EMEA-001523-PIP04-19-M01 - paediatric investigation plan
Guselkumab
PIPHuman
Janssen-Cilag International N.V.
Tel. +32 14602111
E-mail: contact@Janssen-emea.com
P/0399/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab (Tremfya), (EMEA-001523-PIP04-19-M01)